Sogen Data · Datasets · 数据专题

结直肠癌复发轴数据集锦

bulk 转录组

本专题承自 Sogen Data 数据整理体系,逐条人工复核,附研究设计、样本量、平台与 GEO/PubMed 直达链接。

人源bulk 转录组

Human · Bulk RNA-seq

  1. 01 GSE81653 使用人类结直肠癌患者手术肿瘤组织的总RNA,根据复发状态分为Had Recurrence与NonRecurrence组,通过微阵列分析基因表达差异,生成复发预测模型及5FU/FOLFOX疗效预测模型。 人源 · 593 例 · GPL16686 · 2017/06/10

    设计使用人类结直肠癌患者手术肿瘤组织的总RNA,根据复发状态分为Had Recurrence与NonRecurrence组,通过微阵列分析基因表达差异,生成复发预测模型及5FU/FOLFOX疗效预测模型。

    摘要593 FFPE colorectal cancer samples were used to generate three prediction models: Recurrence prediction, 5FU efficacy prediction, and FOLFOX efficacy prediction The recurrence prediction study has 235 samples , 5FU efficacy prediction study has 192 samples, FOLFOX had 166 samples

  2. 02 GSE87211 对363例直肠癌患者及其匹配的黏膜对照样本进行基因表达微阵列分析,同时对230例患者的外周血淋巴细胞DNA进行SNP阵列分析,结合患者的临床数据和长期随访信息,研究直肠癌复发风险与预后相关性。 人源 · 363 例 · GPL13497 · 2017/11/28

    设计对363例直肠癌患者及其匹配的黏膜对照样本进行基因表达微阵列分析,同时对230例患者的外周血淋巴细胞DNA进行SNP阵列分析,结合患者的临床数据和长期随访信息,研究直肠癌复发风险与预后相关性。

    摘要To understand the molecular mechanism of rectal cancer and develop markers for disease prognostication, we generated and explored a dataset from 243 rectal cancer patients by gene expression microarray analysis of cancer samples and matched controls, and SNP-arrays of germline DNA. We found that two of the loci most strongly linked with colorectal cancer (CRC) risk, 8q24 (upstream of MYC) and 18q21 (in the intron of SMAD7), as well as 20q13 (in the intron of LAMA5), are tightly associated with the prognosis of rectal cancer patients. For SNPs on 18q21 (rs12953717 and rs4464148) and 20q13 (rs4925386), alleles that correlate with higher risk for the development of CRC are associated with shorter disease free survival (DFS). However, for rs6983267 on 8q24, the low risk allele is associated with a higher risk for recurrence and metastasis after surgery, and importantly, is strongly correlated with the resistance of CRC cell lines to chemoradiotherapy (CRT). We also found that although MYC expression is dramatically increased in cancer, patients with higher levels of MYC have a better prognosis. The expression of SMAD7 is weakly correlated with DFS. Notably, the presence of the 8q24 and 18q21 SNP alleles is not correlated with expression levels of MYC and SMAD7. rs4464148, and probably rs6983267 and rs4925386, are linked with overall survival time of patients. In conclusion, we show that several CRC risk SNPs detect subpopulations of rectal cancer patients with poor prognosis, and that rs6983267 probably affects prognosis through interfering with the resistance of cancer cells to CRT.

  3. 03 GSE27913 对结直肠癌复发患者与非复发患者的手术切除材料进行基因表达分析,按转移状态(metastatic recurrence, none, metastasis)和肿瘤阶段(2a, 2b, 3a, 3b, 3c, 4, 1)分组,采用激光捕获显微切割提取肿瘤组织并结合全组织分析非肿瘤样本,使用GPL570和GPL3720平台检测总RNA与基因组DNA表达特征,比较不同转移状态与阶段间的基因表达差异。 人源 · 311 例 · GPL570;3720 · 2012/10/16

    设计对结直肠癌复发患者与非复发患者的手术切除材料进行基因表达分析,按转移状态(metastatic recurrence, none, metastasis)和肿瘤阶段(2a, 2b, 3a, 3b, 3c, 4, 1)分组,采用激光捕获显微切割提取肿瘤组织并结合全组织分析非肿瘤样本,使用GPL570和GPL3720平台检测总RNA与基因组DNA表达特征,比较不同转移状态与阶段间的基因表达差异。

    摘要This SuperSeries is composed of the SubSeries listed below.

  4. 04 GSE58394 对300例接受根治性手术的II期结直肠癌患者进行基因表达分析,以筛选与复发相关的预测标志物。使用3,023个探针(1,978个基因)提取转移相关判别基因,通过150例训练样本集确定55个标志物,再将其应用于150例盲测样本集评估预测准确性和预后有效性。检测对象为结直肠癌组织,采用基因表达谱分析方法。 人源 · 300 例 · GPL18709 · 2017/06/10

    设计对300例接受根治性手术的II期结直肠癌患者进行基因表达分析,以筛选与复发相关的预测标志物。使用3,023个探针(1,978个基因)提取转移相关判别基因,通过150例训练样本集确定55个标志物,再将其应用于150例盲测样本集评估预测准确性和预后有效性。检测对象为结直肠癌组织,采用基因表达谱分析方法。

    摘要We have been attempting to stratify the stage II CRC patients into good or poor prognoses based on gene expression signatures of resected specimen. We collected more CRC stage II cases up to 300, and analyzed gene expression for those samples. We selected a set of 3,023 probes (1,978 genes) for extracting metastasis-related discriminator genes. These genes consisted of 491 prognosis related genes identical to the probes on another platform array, and other probes for hybridization and quality control. Using these 3,023 probes, we attempted to select discriminator genes, with the 150 training sample set, resulting 55 markers. We then applied the discriminator set to the second, 150 samples set in a blind test for predictive accuracy and prognostic validity. The multivariate Cox analyses showed the significant parameters to predict the prognosis with a hazard ratio of 3.5 (95% confidence interval, 0.12-0.67; p=0.004). This personalized prognosis is crucial with CRC patients, the predictive performance may deserve serious consideration for possible application to clinic.

  5. 05 GSE40492 对245名直肠癌患者的术前活检样本进行全基因组表达分析,以识别预测治疗结果的分子标志物。其中198例用于分类器训练,47例用于验证。所有样本均采集自接受多模式治疗的患者,采用严格的质量控制措施,提取总RNA并进行表达分析。 人源 · 245 例 · GPL10332 · 2023/03/31

    设计对245名直肠癌患者的术前活检样本进行全基因组表达分析,以识别预测治疗结果的分子标志物。其中198例用于分类器训练,47例用于验证。所有样本均采集自接受多模式治疗的患者,采用严格的质量控制措施,提取总RNA并进行表达分析。

    摘要Background: Validated markers to predict outcome in rectal cancer patients treated with multimodal therapy remain elusive. Identifying molecular profiles for disease prognosis would be required for the design of clinical trials aimed at optimizing risk-adapted therapies. We have therefore used whole genome expression profiling of tumors of a large cohort of patients enrolled in the multicenter trials of the German Rectal Cancer Study Group (GRCSG) to identify molecular profiles for individualized therapy. Methods: We prospectively collected pretherapeutic biopsies from patients (n=300) treated according to the GRCSG trial guidelines from seven different German surgical departments using rigid quality controls. These samples were profiled by global gene expression analysis and a classifier developed to predict postoperative lymph node status and Disease Free Survival (DFS). The performance of the classifier was validated with an independent, prospectively collected set of samples. Findings: The final training and test set included 198 patients. Analyzes for postoperative nodal status and DFS revealed 69 and 674 differentially regulated genes, respectively. Depending on the classifier the accuracy to predict lymph node status ranged from 64% to 69% with negative predictive values between 72% and 74%. Stratification according to DFS resulted in a good (n=99), bad (n=96) and a small very bad prognosis group (n=3). Based on linear discriminant analysis the classifier for positive lymph node status was validated in 47 independent patients and revealed an accuracy of 72% and a positive predictive value of 100%. Thereby, prediction based on molecular profiling is superior to prediction based on conventional clinical markers. Interpretation: Whole genome expression analysis of pretherapeutical biopsies resulted in a molecular classifier of disease prognosis. This classifier was successfully validated. The high positive predictive value for post therapeutic lymph node status allows identification of patients requiring alternative or intensified treatment protocols. These data are currently validated for their clinical applicability and should be taken as basis for future molecular driven clinical trials to develop risk-adapted treatments.

  6. 06 GSE12032 对198例结直肠癌患者进行研究,其中129例用于发现阶段,69例用于验证阶段。研究对象为结直肠癌复发的组织样本,分为阶段II无复发、阶段II复发、阶段III无复发和阶段III复发四组。通过将样本分为训练集和测试集进行重复随机划分,提取鉴别基因,并使用新的69例样本进行验证。检测方式为基于微阵列的基因表达分析,主要比较不同阶段和复发状态下的基因表达差异。 人源 · 198 例 · GPL1291 · 2009/07/02

    设计对198例结直肠癌患者进行研究,其中129例用于发现阶段,69例用于验证阶段。研究对象为结直肠癌复发的组织样本,分为阶段II无复发、阶段II复发、阶段III无复发和阶段III复发四组。通过将样本分为训练集和测试集进行重复随机划分,提取鉴别基因,并使用新的69例样本进行验证。检测方式为基于微阵列的基因表达分析,主要比较不同阶段和复发状态下的基因表达差异。

    摘要Background & Aims. The current staging system for colorectal cancer (CRC) based on TNM classification allows prediction of potential recurrence. However, it does not necessarily make reliable personalized prediction of prognosis. In this paper we describe combination of clinicopathological data and gene signature of dissected tumor specimen with stage II and III CRC patients would improve the situation.. Methods. A total of 1978 CRC were collected over 5 years, and then 371 stage II and 322 stage III of them with more than 45.9 months records were subjected to clinicopathological feature analyses. Out of this collection, 129 stage II and III CRC cases were selected for analyses of gene expression profiles with resected specimen. The gene signatures were analyzed by repeated random divisions of the samples into training and test sets to extract discriminator genes. After testing the applicability of this discriminator set, it was subjected to validation using a newly obtained set of 69 samples. Results. The pathological factors in solo or in combinations could not make personalized recurrence prediction, except for partial success with stage II patients. The gene signature, on the other hand, was capable of producing a set of discriminator genes, though the accuracy was yet to be improved. We observed that the best result was obtained when discriminators were selected from stage II CRC samples and used for prognosis of stage II CRC. When stage III cases were included in the process of discriminator extraction or in the process to validate samples, the results were poorer. Finally, we examined 31 independent stage II samples with a set of 30 such discriminators and were able to obtain results with 78 % accuracy, 90 % negative predictive value (NPV), and 55% positive predictive value (PPV). Conclusions. Independent clinicopathological variables were not able to predict prognosis of individual patient, unless the factors are combined. On the other hand, gene signatures allowed accurate prediction of prognosis for individuals, especially with stage II CRC, suggesting its potential use for selection of best treatment option for individual patients. The accuracy of discriminator prediction will be further improved when we take the evolution of CRC into consideration.

  7. 07 GSE17536 利用高侵袭性小鼠结肠癌细胞与非侵袭性结肠癌细胞的基因表达差异开发转移相关基因表达谱,并通过55例患者(VMC)样本和177例患者(Moffitt)样本的基因表达数据进行优化和验证,采集患者总RNA进行表达分析,比较不同基因型和处理组的基因表达差异以预测结肠癌复发和死亡风险。 人源 · 177 例 · GPL570 · 2009/11/14

    设计利用高侵袭性小鼠结肠癌细胞与非侵袭性结肠癌细胞的基因表达差异开发转移相关基因表达谱,并通过55例患者(VMC)样本和177例患者(Moffitt)样本的基因表达数据进行优化和验证,采集患者总RNA进行表达分析,比较不同基因型和处理组的基因表达差异以预测结肠癌复发和死亡风险。

    摘要Background and Aims: Staging inadequately predicts metastatic risk in colon cancer patients. We used a gene expression profile derived from invasive murine colon cancer cells that were highly metastatic in an immunocompetent mouse model to identify colon cancer patients at risk for recurrence in a phase I, exploratory biomarker study. Methods: 55 colorectal cancer patients from Vanderbilt Medical Center (VMC) were used as the training dataset and 177 patients from the Moffitt Cancer Center were used as the independent dataset. The metastasis-associated gene expression profile developed from the mouse model was refined using comparative functional genomics in the VMC gene expression profiles to identify a 34-gene classifier associated with high risk of metastasis and death from colon cancer. A recurrence score derived from the biologically based classifier was tested in the Moffitt dataset. Results: A high score was significantly associated with increased risk of metastasis and death from colon cancer across all pathological stages and specifically in stage II and stage III patients. The recurrence score was shown to independently predict risk of cancer recurrence and death in both univariate and multivariate models. For example, among stage III patients, a high score translated to increased relative risk for cancer recurrence (hazard ratio = 4.7 (95% CI=1.566-14.05)). Furthermore, the recurrence score identified stage III patients whose five-year recurrence-free survival was >88% and for whom adjuvant chemotherapy did not provide improved survival. Conclusion: Our biologically based gene expression profile yielded a potentially useful classifier to predict cancer recurrence and death independently of conventional measures in colon cancer patients. Keywords: Functional genomics, metastatic colon cancer, mouse model, human colon cancer

  8. 08 GSE101651 研究对象为结直肠癌复发和转移样本,采集不同部位的组织进行总 RNA 提取,采用 RNA-Seq 技术检测表达特征,比较不同组织来源的 RNA 表达差异。 人源 · 159 例 · GPL17586;23782;11154 · 2019/03/04

    设计研究对象为结直肠癌复发和转移样本,采集不同部位的组织进行总 RNA 提取,采用 RNA-Seq 技术检测表达特征,比较不同组织来源的 RNA 表达差异。

    摘要This SuperSeries is composed of the SubSeries listed below.

  9. 09 GSE106584 对156例结直肠癌患者样本进行全转录组基因表达分析,采用Affymetrix Human Transcriptome Array 2.0平台检测总RNA,旨在识别预测II-III期结直肠癌患者化疗反应的生物标志物。 人源 · 156 例 · GPL17586 · 2021/11/04

    设计对156例结直肠癌患者样本进行全转录组基因表达分析,采用Affymetrix Human Transcriptome Array 2.0平台检测总RNA,旨在识别预测II-III期结直肠癌患者化疗反应的生物标志物。

    摘要Defining molecular features that can predict the response to chemotherapy for stage II-III colorectal cancer (CRC) patients remains challenging in cancer research. Most available clinical samples are Formalin-Fixed and Paraffin-Embedded (FFPE). Affymetrix GeneChip® Human Transcriptome Array 2.0 (HTA) is one platform marketed for high-throughput gene expression profiling for FFPE tissue samples. In this study, we analyzed the whole transcriptom gene expression of 156 CRC patient samples measured by this platform to identify biomarkers predicting the response to chemotherapy for stage II-III CRC patients.

  10. 10 GSE21510 对结直肠癌复发患者手术切除组织进行基因表达分析,采用激光捕获显微切割(LCM)和均质化处理分组,通过寡核苷酸微阵列检测癌细胞表达谱,比较远处转移与无转移样本的差异。选取过表达候选基因后,利用定量 RT-PCR 验证其 mRNA 表达,通过免疫组化分析蛋白表达及定位,并评估其与临床病理特征的关系。 人源 · 148 例 · GPL570 · 2011/02/28

    设计对结直肠癌复发患者手术切除组织进行基因表达分析,采用激光捕获显微切割(LCM)和均质化处理分组,通过寡核苷酸微阵列检测癌细胞表达谱,比较远处转移与无转移样本的差异。选取过表达候选基因后,利用定量 RT-PCR 验证其 mRNA 表达,通过免疫组化分析蛋白表达及定位,并评估其与临床病理特征的关系。

    摘要Purpose: This study aimed to identify a novel biomarker or a target of treatment for colorectal cancer (CRC). Experimental Design: The expression profiles of cancer cells in 104 patients with CRC were examined using laser microdissection and oligonucleotide microarray analysis. Overexpression in CRC cells especially in patients with distant metastasis was a prerequisite to select candidate genes. The mRNA expression of candidate gene was investigated by quantitative reversetranscription polymerase chain reaction (RT-PCR) in 77 patients as a validation study. We analyzed the protein expression and localization of the candidate gene by immunohistochemical study, and investigated the relationship between the expression and the clinicopathological feature in 274 CRC patients. Results: We identified 6 genes as candidates related to distant metastasis in CRC patients by microarray analysis. Among these genes, Osteoprotegerin (OPG) is known to have an association with aggressiveness in several cancers through inhibiting apoptosis by neutralizing the function of tumor necrosis factor related apoptosis inducing ligand (TRAIL). The mRNA expression of OPG in cancer tissues was significantly higher in patients with distant metastasis than those without metastasis. The overexpression of OPG protein was significantly associated with worse overall survival and relapse free survival (RFS). Moreover, the overexpression of OPG protein was an independent risk factor for recurrence of CRC. Conclusion: The overexpression of OPG would be a predictive biomarker of recurrence and a target of the treatment for CRC.

  11. 11 GSE27854 对115名结直肠癌患者的手术切除材料进行基因表达分析,采用Affymetrix Gene Chip平台,检测激光捕获显微解剖样本的mRNA表达谱。同时分析拷贝数变化,提取共同基因作为候选,并通过定量逆转录聚合酶链反应(RT-PCR)和免疫组化验证其表达,比较不同临床病理特征下的表达差异。 人源 · 115 例 · GPL570 · 2012/10/16

    设计对115名结直肠癌患者的手术切除材料进行基因表达分析,采用Affymetrix Gene Chip平台,检测激光捕获显微解剖样本的mRNA表达谱。同时分析拷贝数变化,提取共同基因作为候选,并通过定量逆转录聚合酶链反应(RT-PCR)和免疫组化验证其表达,比较不同临床病理特征下的表达差异。

    摘要Purpose: The purpose of this study is to identify a novel biomarker related with distant metastases of colorectal cancer (CRC). Experimental Design: We investigated mRNA expression profiles in 115 patients with CRC using an Affymetrix Gene Chip, and copy number profiles in 122 patients with CRC using an Affymetrix DNA Sty array. Genes in common between copy number and expression data were extracted as candidate genes. We analyzed the mRNA expression of candidate gene by quantitative reverse transcription polymerase chain reaction (RT-PCR) in 86 patients as a validation study. Furthermore, we analyzed the protein expression of candidate gene by immunohistochemical study in 269 patients, and investigated the relationship between protein expression and clinicopathologic features. Results: By the combination of copy number analysis and gene expression analysis, We extracted 2 candidate genes related with distant metastases of CRC. Several reports show that NUCKS1, one of candidate genes, is overexpressed in several cancer tissues. But a study about the relationship between NUCKS1 and CRC is none. The mRNA expression of NUCKS1 in cancer tissues was significantly higher than those in normal tissues. Overexpression of NUCKS1 protein was associated with significantly worse relapse-free survival of CRC. Overexpression of NUCKS1 protein was an independent risk factor for recurrence of CRC. Conclusion: The overexpression of NUCKS1 would be a new biomarker predicting recurrence after colorectal surgery.

  12. 12 GSE18105 针对结直肠癌复发患者,分析手术切除组织的基因表达。将样本分为复发组与非复发组,采用微阵列检测基因表达差异,并通过定量实时逆转录PCR验证候选基因在肿瘤组织与相邻正常组织间的表达关系,比较复发组与非复发组的表达差异及肿瘤与正常组织的表达差异。 人源 · 111 例 · GPL570 · 2010/02/04

    设计针对结直肠癌复发患者,分析手术切除组织的基因表达。将样本分为复发组与非复发组,采用微阵列检测基因表达差异,并通过定量实时逆转录PCR验证候选基因在肿瘤组织与相邻正常组织间的表达关系,比较复发组与非复发组的表达差异及肿瘤与正常组织的表达差异。

    摘要Distant metastasis is the major causes of death in colorectal cancer (CRC) patients. In order to identify genes influencing the prognosis of patients with CRC, we compared gene expression in primary tumors with and without distant metastasis using an oligonucleotide microarray. We also examined the expression of the candidate gene in 100 CRC patients by quantitative real-time reverse transcription PCR and studied the relationship between its expression and the prognosis of patients with CRC. As a result, we identified MUC12 as a candidate gene involved in metastasis processes by microarray analysis. Quantitative real-time reverse transcription PCR showed that MUC12 expression was significantly lower in cancer tissues than in adjacent normal tissues (P < 0.001). In stage II and stage III CRC, patients with low expression showed worse disease-free survival (P = 0.038). Multivariate analysis disclosed that MUC12 expression status was an independent prognostic factor in stage II and stage III CRC (relative risk, 9.532; 95% confidence interval, 2.303-41.905; P = 0.002). This study revealed the prognostic value of MUC12 expression in CRC patients. Moreover, our result suggests MUC12 expression is a possible candidate gene for assessing postoperative adjuvant therapy for CRC patients.

  13. 13 GSE107422 对110例结直肠癌患者原发肿瘤样本进行RNA测序,分析基因表达与疾病复发的关联。 人源 · 110 例 · GPL11154 · 2019/10/29

    设计对110例结直肠癌患者原发肿瘤样本进行RNA测序,分析基因表达与疾病复发的关联。

    摘要The objective of this study is to identify a gene set to predict recurrence of colorectal cancer (CRC) patients. We generated RNA-seq data of 110 primary CRC samples and identified significant genes associated with recurrence of CRC. Through diverse statistical methods including generalized linear model likelihood ratio test, significant 10 genes were identified. In the validation cohorts, a risk classifier consisting of the 10 genes was an independent risk factor in colorectal cancers.

  14. 14 GSE56699 对72例人类直肠癌原发肿瘤石蜡包埋样本进行分子特征分析,包括58例术前样本和14例手术样本,采用基因芯片技术检测总RNA表达,比较不同样本的表达特征。 人源 · 72 例 · GPL14951 · 2015/01/27

    设计对72例人类直肠癌原发肿瘤石蜡包埋样本进行分子特征分析,包括58例术前样本和14例手术样本,采用基因芯片技术检测总RNA表达,比较不同样本的表达特征。

    摘要We noticed that a recently identified poor prognosis stem/serrated molecular subtype of colorectal cancer (CRC) is characterized by up-regulation of transcripts known to be also expressed by stromal cells. To better define the origin of such transcripts, we analyzed RNAseq and microarray datasets from CRC mouse xenografts, where human cancer cells are supported by murine stroma. The analysis revealed that mRNA levels of stem/serrated subtype genes are mostly due to stromal expression, even when the stromal fraction is below 5%. Indeed, a classifier based on genes exclusively expressed by cancer-associated fibroblasts was significantly associated, in multiple datasets, to poor prognosis of CRC and to radioresistance of rectal cancer.

  15. 15 GSE39084 研究对象为散发性早发 colorectal carcinoma 患者,根据年龄(<45 或 >60 岁)和 mismatch repair 状态分组,采集冷冻的原发性 colorectal 肿瘤组织进行表达检测,比较不同年龄组和 mismatch repair 状态组的基因表达差异。 人源 · 70 例 · GPL570 · 2014/08/04

    设计研究对象为散发性早发 colorectal carcinoma 患者,根据年龄(<45 或 >60 岁)和 mismatch repair 状态分组,采集冷冻的原发性 colorectal 肿瘤组织进行表达检测,比较不同年龄组和 mismatch repair 状态组的基因表达差异。

    摘要Sporadic early onset colorectal carcinoma (EOCRC) is a growing problem that remains poorly understood. Clinical specificities and mechanisms of tumorigenesis might be relevant to both diagnosis and treatment. In this prospective study, clinicopathological features, genomic and gene expression profiles of sporadic EOCRC were compared to other well defined groups of CRC.

  16. 16 GSE17537 利用小鼠高转移性结肠癌细胞与低转移性结肠癌细胞的基因表达差异构建转移相关基因表达谱,并通过55例患者(Vanderbilt Medical Center)样本和177例患者(Moffitt Cancer Center)样本的基因表达数据进行优化和验证,最终开发出一个34基因分类器用于预测结直肠癌复发和死亡风险。 人源 · 55 例 · GPL570 · 2009/11/14

    设计利用小鼠高转移性结肠癌细胞与低转移性结肠癌细胞的基因表达差异构建转移相关基因表达谱,并通过55例患者(Vanderbilt Medical Center)样本和177例患者(Moffitt Cancer Center)样本的基因表达数据进行优化和验证,最终开发出一个34基因分类器用于预测结直肠癌复发和死亡风险。

    摘要Background and Aims: Staging inadequately predicts metastatic risk in colon cancer patients. We used a gene expression profile derived from invasive murine colon cancer cells that were highly metastatic in an immunocompetent mouse model to identify colon cancer patients at risk for recurrence in a phase I, exploratory biomarker study. Methods: 55 colorectal cancer patients from Vanderbilt Medical Center (VMC) were used as the training dataset and 177 patients from the Moffitt Cancer Center were used as the independent dataset. The metastasis-associated gene expression profile developed from the mouse model was refined using comparative functional genomics in the VMC gene expression profiles to identify a 34-gene classifier associated with high risk of metastasis and death from colon cancer. A recurrence score derived from the biologically based classifier was tested in the Moffitt dataset. Results: A high score was significantly associated with increased risk of metastasis and death from colon cancer across all pathological stages and specifically in stage II and stage III patients. The recurrence score was shown to independently predict risk of cancer recurrence and death in both univariate and multivariate models. For example, among stage III patients, a high score translated to increased relative risk for cancer recurrence (hazard ratio = 4.7 (95% CI=1.566-14.05)). Furthermore, the recurrence score identified stage III patients whose five-year recurrence-free survival was >88% and for whom adjuvant chemotherapy did not provide improved survival. Conclusion: Our biologically based gene expression profile yielded a potentially useful classifier to predict cancer recurrence and death independently of conventional measures in colon cancer patients. Keywords: Functional genomics, metastatic colon cancer, mouse model, human colon cancer

  17. 17 GSE18088 对53例UICC II期结直肠癌患者肿瘤组织总RNA进行基因表达分析,同时通过免疫组化检测五种已发表分类基因的蛋白表达。样本按复发状态分为疾病无复发组(DF)和复发组(R),采用Affymetrix GeneChips(GPL570)平台进行RNA测序,利用Nearest Shrunken Centroids方法建立预后特征,比较DF与R组间基因表达差异。 人源 · 53 例 · GPL570 · 2011/04/10

    设计对53例UICC II期结直肠癌患者肿瘤组织总RNA进行基因表达分析,同时通过免疫组化检测五种已发表分类基因的蛋白表达。样本按复发状态分为疾病无复发组(DF)和复发组(R),采用Affymetrix GeneChips(GPL570)平台进行RNA测序,利用Nearest Shrunken Centroids方法建立预后特征,比较DF与R组间基因表达差异。

    摘要Background Published multi-gene classifiers suggested outcome prediction for patients with stage UICC II colon cancer based on different gene expression signatures. However, there is currently no translation of these classifiers for application in routine diagnostic. Therefore, we aimed at validating own and published gene expression signatures employing methods which enable RNA and protein detection in routine diagnostic specimens. Results Immunohistochemistry was applied to 68 stage UICC II colon cancers to determine the protein expression of five selected previously published classifier genes (CDH17, LAT, CA2, EMR3, and TNFRSF11A). Correlation of protein expression data with clinical outcome within a 5-year post-surgery course failed to separate patients with a disease-free follow-up [Group DF] and relapse [Group R]). In addition, RNA from macrodissected tumor samples from 53 of these 68 patients was profiled on Affymetrix GeneChips (HG-U133 Plus 2.0). Prognostic signatures were generated by Nearest Shrunken Centroids with cross-validation. Although gene expression profiling allowed the identification of differentially expressed genes between the groups DF and R, a stable classification and prognosis signature was not discernable in our data. Furthermore, the application of previously published gene signatures consisting of 22 and 19 genes, respectively, to our gene expression data set using ‘global tests’ and leave-one-out cross-validation was unable to predict clinical outcome (prediction rate 75.5% and 64.2%; n.s.). T-stage was the only independent prognostic factor for relapse in multivariate analysis with established clinical and pathological parameters including microsatellite status. Conclusions Our protein and gene expression analyses currently do not support application of molecular classifiers for prediction of clinical outcome in routine diagnostic as a basis for patient-orientated therapy in stage UICC II colon cancer. Further studies are needed to develop prognosis signatures applicable in patient care.

  18. 18 GSE31595 对37名II和III期结直肠癌患者的肿瘤样本进行基因表达分析,比较复发与非复发患者的基因表达差异。 人源 · 37 例 · GPL570 · 2011/09/01

    设计对37名II和III期结直肠癌患者的肿瘤样本进行基因表达分析,比较复发与非复发患者的基因表达差异。

    摘要Purpose: A 128-gene signature has been proposed to predict poor outcomes in patients with stage II and III colorectal cancer. In the present study we aimed to validate this previously published 128-gene signature on external and independent data from patients with stage II and III colon cancer.

  19. 19 GSE4526 对36例接受结直肠癌根治性手术切除的患者进行研究,其中23例未复发(Recurrence(-)),13例发生复发(Recurrence(+)),包括肝转移、肺转移及远处淋巴结转移。采集手术切除标本的总RNA,采用Affymetrix Human Genome U133 Plus 2.0芯片进行基因表达分析,比较复发组与非复发组的基因表达差异,以识别预测复发的分子标志物。 人源 · 36 例 · GPL570 · 2010/08/31

    设计对36例接受结直肠癌根治性手术切除的患者进行研究,其中23例未复发(Recurrence(-)),13例发生复发(Recurrence(+)),包括肝转移、肺转移及远处淋巴结转移。采集手术切除标本的总RNA,采用Affymetrix Human Genome U133 Plus 2.0芯片进行基因表达分析,比较复发组与非复发组的基因表达差异,以识别预测复发的分子标志物。

    摘要Samples were taken from colorectal cancers in surgically resected specimens in 36 colorectal cancer patients. The expression profiles were determined using Affymetrix Human Genome U133 Plus 2.0 arrays. Comparison between the sample groups allow to identify a set of discriminating genes that can be used for molecular markers for predicting recurrence. Keywords: repeat

  20. 20 GSE106535 对35例人类结直肠癌肿瘤样本的总RNA进行基因表达分析,采用Affymetrix Human Exon 1.0 ST芯片检测转录水平,同时通过RT-qPCR测定D133TP53 mRNA表达量,利用Spearman相关分析识别与D133TP53表达显著相关的364个基因,并通过Pantherdb过代表测试分析基因集富集情况。 人源 · 35 例 · GPL5175 · 2018/02/14

    设计对35例人类结直肠癌肿瘤样本的总RNA进行基因表达分析,采用Affymetrix Human Exon 1.0 ST芯片检测转录水平,同时通过RT-qPCR测定D133TP53 mRNA表达量,利用Spearman相关分析识别与D133TP53表达显著相关的364个基因,并通过Pantherdb过代表测试分析基因集富集情况。

    摘要D122p53 mice (a model of D133p53 isoform) are tumour prone, have extensive inflammation and elevated serum IL-6. To investigate the role of IL-6 we crossed ∆122p53 mice with IL-6 deficient mice. Here we show that loss of IL-6 reduced JAK-STAT signalling, tumour incidence, and metastasis. We also show that D122p53 activates RhoA-ROCK signalling leading to tumour cell invasion which is IL-6 dependent and can be reduced by inhibition of JAK-STAT and RhoA-ROCK pathways. Similarly, we show that Δ133p53 activates the these pathways, resulting in invasive and migratory phenotypes, in colorectal cancer cells. Gene expression analysis of colorectal tumours showed enrichment of GPCR signalling associated with D133TP53 mRNA. Patients with elevated D133TP53 mRNA levels had a shorter disease free survival. Our results suggest that D133p53 promotes tumour invasion by activation of the JAK-STAT and RhoA-ROCK pathways and that patients whose tumours have high D133p53 may benefit from therapies targeting these pathways. In this dataset, we included the gene expression data from 35 colorectal cancers. These data were used to identify a list of enriched genesets associated with D133TP53 mRNA expression in colorectal tumours

  21. 21 GSE122246 对接受标准辅助化疗的 III 期结直肠癌患者按无病生存期结果分为预后不良与良好两组,提取新鲜冷冻组织样本进行 RNA 测序,通过比较两组间差异表达基因识别预测化疗反应的分子生物标志物。 人源 · 24 例 · GPL17303 · 2020/05/03

    设计对接受标准辅助化疗的 III 期结直肠癌患者按无病生存期结果分为预后不良与良好两组,提取新鲜冷冻组织样本进行 RNA 测序,通过比较两组间差异表达基因识别预测化疗反应的分子生物标志物。

    摘要Five-year overall survival of stage III colorectal cancer (CRC) patients treated with standard adjuvant chemotherapy (ACHT) is highly variable. Genomic biomarkers and/or transcriptomic profiles identified lack of adequate validation. Aim of our study was to identify and validate molecular biomarkers predictive of ACHT response in stage III CRC patients by a transcriptomic approach. From a series of CRC patients who received ACHT, two stage III extreme cohorts (unfavorable vs. favorable prognosis) were selected. RNA sequencing was performed from fresh frozen explants. Tumors were characterized for somatic mutations. Validation was performed in stage III CRC patients extracted from two GEO datasets. According to disease free survival (DFS), 108 differentially expressed genes (104/4 up/downregulated in the unfavorable prognosis group) were identified. Among 104 upregulated genes, 42 belonged to olfactory signaling pathways, 62 were classified as pseudogenes (n = 17), uncharacterized noncoding RNA (n = 10), immune response genes (n = 4), microRNA (n = 1), cancer-related genes (n = 14) and cancer-unrelated genes (n = 16). Three out of four down-regulated genes were cancer-related. Mutational status (i.e., RAS, BRAF, PIK3CA) did not differ among the cohorts. In the validation cohort, multivariate analysis showed high PNN and KCNQ1OT1 expression predictive of shorter DFS in ACHT treated patients (p = 0.018 and p = 0.014, respectively); no difference was observed in untreated patients. This is the first study that identifies by a transcriptomic approach and validates PNN and KCNQ1OT1 as molecular biomarkers predictive of chemotherapy response in stage III CRC patients. After a further validation in an independent cohort, PNN and KCNQ1OT1 evaluation could be proposed to prospectively identify stage III CRC patients benefiting from ACHT.

  22. 22 GSE60697 对20名III期结直肠癌患者手术切除后的组织样本进行基因表达分析,按无复发生存期(RFS>3年)与复发生存期(RFS<3年)分组,采集速冻组织进行微阵列检测,比较两组间基因表达差异。 人源 · 20 例 · GPL570 · 2014/08/26

    设计对20名III期结直肠癌患者手术切除后的组织样本进行基因表达分析,按无复发生存期(RFS>3年)与复发生存期(RFS<3年)分组,采集速冻组织进行微阵列检测,比较两组间基因表达差异。

    摘要We obtained snap-frozen tissue samples from 20 colorectal cancer (CRC) patients with stage III disease who had undergone curative resection. The expression profiles were determined using Affymetrix Human Genome U133Plus 2.0 arrays. We used microarrays to identify potential gene deregulation correlated with the outcomes of colon cancer patients.

  23. 23 GSE2630 对 Dukes´B 期结直肠癌患者冷冻肿瘤组织进行基因表达谱分析,按复发状态分为两组,采用高密度寡核苷酸微阵列检测,经量化归一化处理后通过两种统计方法筛选差异基因,比较复发组与非复发组基因表达特征。 人源 · 16 例 · GPL2006 · 2005/05/07

    设计对 Dukes´B 期结直肠癌患者冷冻肿瘤组织进行基因表达谱分析,按复发状态分为两组,采用高密度寡核苷酸微阵列检测,经量化归一化处理后通过两种统计方法筛选差异基因,比较复发组与非复发组基因表达特征。

    摘要Purpose: The benefit of postoperative adjuvant chemotherapy in patients with Dukes´ B colorectal cancer is still uncertain and its routine use is not recommended. The five years survival rate is approximately 75% and identification of the patients at high risk of recurrence would represent an important strategy for the use of adjuvant chemotherapy. In this study we identify new prognostic markers for tumor relapse in Dukes´ B colon cancer patients. Patients and Methods: We retrospectively analyzed gene expression profiles in frozen tumor specimens from 16 patients with Dukes´ B colorectal cancer by using high density oligonucleotide microarrays. Data were normalized and subsequently analyzed with two different statistical procedures. The intensity value associated to each spot is the result of subtracting a gaussian function of the noise from the foreground values {Kooperberg, 2002}. After this background subtraction, base 2 logarithms of all data were calculated and genes with more than two missing values were excluded from the analysis. The remaining missing values were replaced by using the KNN imputation method {Troyanskaya, 2001}. The great number of genes present in the microarray allowed us to consider that the overall fluorescence intensity must be the same for all slides, as the vast majority of genes will not change their expression between the two conditions tested. So we used the quantile normalization method {Bolstad, 2003}, which equalizes not only the average intensity but also the range of intensity values between slides. We decided to use two different statistical procedures in the search of significant differences in gene expression between the relapsed and non-relapsed patients. Only the genes selected by both statistical procedures were considered as differentially expressed between relapsed and non-relapsed patients. The first test was a permutation t-test for comparison of two means {Dudoit, 2003} and the second one a variation of the Fisher test based on the work presented by Iizuka et al. {Iizuka, 2003} in which they searched for the optimal number of genes that could differentiate between two groups of samples. Briefly, we used the same algorithms for the calculation of the Fisher criterion, but instead of looking for the optimal subset of genes able to differentiate between groups, what requires a lot of computing capacity, we tried different numbers of candidate genes and selected a number which yielded very good classification results when evaluated by means of Fast ICA {Lee, 2003} and Hierarchical Clustering {Everitt, 1974}. The procedure consisted of selecting the 30 genes with the highest Fisher criterion value in 6 rounds of iteration, each round leaving one sample of the relapsed group and two of the non-relapsed group out of the calculations (a variant of the “leave one out” method). We selected the genes present in at least 3 of the iterations. The intersection of the groups of genes selected by the two statistical procedures was selected as a prognostic signature for relapse in Dukes´stage B colon cancer. Results: Our results show a group of 48 genes differentially expressed between the relapsed and non-relapsed groups with an associated probability below 0,001 in the t test. Another statistical procedure based on the Fisher criterion resulted in 11 genes able to separate both groups. In order to minimize false positives we only considered a good gene signature the 8 genes selected by both statistical procedures. These genes are ribosomal protein S5, chromodomain helicase DNA binding protein 2, lysosomal ATPase V0 subunit A isoform 1, zinc finger protein 148, brain protein I3 (BRI3), hypothetical protein MGC23401 and one unknown clone. In order to verify the obtained results, the differential expression of the first two genes was confirmed by real time PCR. Keywords: repeat sample

人源·鼠源bulk 转录组

Human · Mouse · Bulk RNA-seq

  1. 01 GSE17538 对结直肠癌复发的bulk RNA测序研究,采集了人类和小鼠样本,按年龄、AJCC分期、组织位置和癌细胞类型分组,检测总RNA表达,比较不同组别间的生存和复发情况。 人源·鼠源 · 244 例 · GPL570;1261 · 2009/11/14

    设计对结直肠癌复发的bulk RNA测序研究,采集了人类和小鼠样本,按年龄、AJCC分期、组织位置和癌细胞类型分组,检测总RNA表达,比较不同组别间的生存和复发情况。

    摘要This SuperSeries is composed of the SubSeries listed below.

微信二维码

课题合作 · 扫码加微信

bioinformaticsboy